NEUROMUSCULAR junction failure causes severe muscle weakness in sarcopenia by reducing postsynaptic endplate action potential gain. While age-related physical decline has long been attributed primarily to the progressive loss of muscle mass, emerging clinical evidence indicates that muscle weakness rather than muscle volume drives functional disability. Addressing this disconnect requires examining the neural interface where motor neurons stimulate skeletal fibers to contract.
Using stimulated single-fiber electromyography in the vastus lateralis, investigators evaluated older adults with self-reported mobility limitations alongside healthy adult controls. The weak older cohort exhibited an approximate 250% increase in mean electrophysiological jitter and marked impulse blocking across up to 35% of assessed motor endplates. Both jitter and blocking correlated inversely with leg extensor strength normalized to quadriceps muscle volume. These clinical observations demonstrate that neuromuscular junction failure directly impairs volitional force generation, independent of muscle atrophy.
Parallel investigations across aged rodents and human muscle biopsies revealed that this transmission defect stems from a localized loss of postsynaptic excitability rather than overt motor nerve denervation. Confocal morphometric evaluations demonstrated structurally intact synapses with normal nerve terminal overlap, yet highlighted a selective depletion of voltage-gated sodium channel NaV1.4 at the motor endplate and parajunctional folds. Intracellular microelectrode recordings confirmed that aged fibers require significantly greater electrical thresholds to elicit an action potential at the junction. Furthermore, acute NaV1.4 blockade in adult rats with $\mu$-conotoxin reproduced the high jitter and blocking characteristic of sarcopenic neuromuscular junctions.
Because skeletal muscle ClC-1 chloride channels serve as primary negative regulators of membrane excitability, pharmacological ClC-1 inhibition was investigated to restore action potential firing. In aged rodent models exhibiting transmission failure, oral administration of small-molecule ClC-1 inhibitors restored stimulated muscle force and rescued over half of the age-related force deficit. Blinded multidose regimens also produced substantial improvements in voluntary grip strength, which promptly reverted upon treatment cessation. These therapeutic results suggest that neuromuscular junction failure represents a modifiable physiological defect, presenting a viable target to preserve mobility in aging populations.
Reference
Arnold WD et al. Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition. J Clin Invest. 2026;136(17):e190646.
Featured Image: Glama22 on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
